Abstract
Transforming Growth Factor β (TGFβ) signaling influences most aspects of cellular function in addition to playing a major role in organ development, remodeling, and repair. Given the wide range of effects induced by TGFβ, it is not surprising that alterations in TGFβ signaling have been implicated in development and progression of many different cancer types. Within the context of breast cancer itself, TGFβ is known to have a dual nature, being both tumorsuppressive during early breast cancer development and tumor-promoting during breast cancer metastasis. Targets for breast cancer therapeutics are greatly needed to decrease morbidity and mortality from this devastating disease. Here, we summarize what is known about TGFβ in breast cancer progression and discuss potential TGFβ targets for breast cancer therapeutics.
Keywords: Apoptosis, breast cancer, cytostatic, immune regulation, metastasis, stem cell, TGFβ
Current Drug Targets
Title: Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Volume: 11 Issue: 9
Author(s): Sarah E. Baxley and Rosa Serra
Affiliation:
Keywords: Apoptosis, breast cancer, cytostatic, immune regulation, metastasis, stem cell, TGFβ
Abstract: Transforming Growth Factor β (TGFβ) signaling influences most aspects of cellular function in addition to playing a major role in organ development, remodeling, and repair. Given the wide range of effects induced by TGFβ, it is not surprising that alterations in TGFβ signaling have been implicated in development and progression of many different cancer types. Within the context of breast cancer itself, TGFβ is known to have a dual nature, being both tumorsuppressive during early breast cancer development and tumor-promoting during breast cancer metastasis. Targets for breast cancer therapeutics are greatly needed to decrease morbidity and mortality from this devastating disease. Here, we summarize what is known about TGFβ in breast cancer progression and discuss potential TGFβ targets for breast cancer therapeutics.
Export Options
About this article
Cite this article as:
E. Baxley Sarah and Serra Rosa, Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling, Current Drug Targets 2010; 11 (9) . https://dx.doi.org/10.2174/138945010792006771
DOI https://dx.doi.org/10.2174/138945010792006771 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nardilysin, A Basic Residues Specific Metallopeptidase That Mediates Cell Migration and Proliferation
Protein & Peptide Letters Recent Advance in the Design of Small Molecular Modulators of Estrogen-Related Receptors
Current Pharmaceutical Design Antiangiogenic Drugs and Tyrosine Kinases
Anti-Cancer Agents in Medicinal Chemistry Targeting Cytotoxic Conjugates of Somatostatin, Luteinizing Hormone- Releasing Hormone and Bombesin to Cancers Expressing Their Receptors: A “Smarter” Chemotherapy
Current Pharmaceutical Design Anticancer Activity and In Silico ADMET Properties of 2,4,5-Trisubstitutedthiazole Derivatives
Current Drug Metabolism The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Subject Index To Volume 1
Current Gene Therapy Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry The CXCR4/SDF-1 Chemokine Axis: A Potential Therapeutic Target for Bone Metastases?
Current Pharmaceutical Design Bacterial Biotransformation and Anticancer Activities of Betulin against A549, HepG2 and 5RP7 Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination?
Current Genomics The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas
Current Pharmaceutical Design Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry A Cell Culture Model for the Assessment of the Chemopreventive Potential of Dietary Compounds.
Current Nutrition & Food Science Inhibition of Fatty Acid Synthase by Polyphenols
Current Medicinal Chemistry Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Potential Anticancer Agents. I. Synthesis of Isoxazole Moiety Containing Quinazoline Derivatives and Preliminarily in vitro Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Status of Anti-Lung Cancer Drug Patents Applications in China from 2003 to 2012
Recent Patents on Anti-Cancer Drug Discovery The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry